HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Abstract
We have carried out a stratified phase II study of sorafenib (So) in patients with advanced angiosarcoma (n = 32) and epithelioid hemangioendothelioma (n = 13). This report concerns the correlative analysis of the predictive values of circulating pro/anti-angiogenetic biomarkers. Using the ELISA method (R&D Systems), circulating biomarkers (VEGF-A, in picograms per milliliter), thrombospondin-1 (TSP1, in micrograms per milliliter), stem cell factor (SCF, in picograms per milliliter), placental growth factor (PlGF, in picograms per milliliter), VEGF-C (in picograms per milliliter), and E-selectin (in nanograms per milliliter) were measured before So treatment and after 7 days. VEGF-A (mean value 475 vs. 541, p = 0.002), TSP1 (16 vs. 24, p = 0.0002), and PlGF (20.9 vs. 40.7, p = 0.0001) significantly increased during the treatment. Treatment did not affect the levels of SCF, VEGF-C, and E-selectin. Only two biomarkers were associated with better outcome as follows: VEGF-A and PlGF. Best objective response and non-progression at 180 days were associated with low level of VEGF-A at baseline (p = 0.04 and 0.03, respectively). There was a correlation between the circulating level of VEGF-A and time to progression (TTP) (r = -0.47, p = 0.001). Best objective response and non-progression at 180 days were not associated with baseline level of PIGF, but there was a correlation between the circulating level of PIGF at baseline and TTP. Low level of VEGF-A at baseline (<500) was significantly associated with better outcome.
AuthorsNicolas Penel, Isabelle Ray-Coquard, Christine Bal-Mahieu, Christine Chevreau, Axel Le Cesne, Antoine Italiano, Emmanuelle Bompas, Stéphanie Clisant, Brigitte Baldeyrou, Amélie Lansiaux, Yves-Marie Robin, Jacques-Olivier Bay, Sophie Piperno-Neumann, Jean-Yves Blay, Charles Fournier
JournalTargeted oncology (Target Oncol) Vol. 9 Issue 3 Pg. 273-7 (Sep 2014) ISSN: 1776-260X [Electronic] France
PMID24218035 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Phenylurea Compounds
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Sorafenib
Topics
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (blood)
  • Enzyme-Linked Immunosorbent Assay
  • Hemangioendothelioma, Epithelioid (blood, drug therapy)
  • Hemangiosarcoma (blood, drug therapy)
  • Humans
  • Niacinamide (analogs & derivatives, therapeutic use)
  • Phenylurea Compounds (therapeutic use)
  • Sorafenib
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: